对于老年2型糖尿病患者的痴呆症,他类药物治疗有 Delirium
Mingyang Sun1, Xiaoling Wang1,2, Zhongyuan Lu1,2
1Department of Anesthesiology and Perioperative Medicine, People's Hospital of Zhengzhou University, Henan Provincial People's Hospital, Zhengzhou, Henan, China.
Diabetology & metabolic syndrome
|December 22, 2025
概括
在患有2型糖尿病的老年人中,使用他类药物并有 delirium 病史显著降低了痴呆症风险和死亡率. 较高的他类药物剂量显示出更大的保护作用,这表明这种高危人群在痴呆症预防中可能发挥作用.
科学领域:
- 老年学是指老年学的学科.
- 神经学 神经学
- 药理学 药理学是指药理学的学科.
背景情况:
- 患有2型糖尿病 (T2DM) 的老年人妄与认知衰退和痴呆有关.
- 虽然他类药物的神经保护作用可能会减轻这种风险,但它们对T2DM患者的疗效尚不清楚.
研究的目的:
- 调查在老年T2DM患者中使用他类药物和痴呆风险之间的关联,这些患者有 delirium 的病史.
主要方法:
- 分析了一组65岁以上的2型糖尿病患者和先前妄住院的患者队列 (2008-2022年).
- 根据每年累计定义的每日剂量 (cDDD) 定义,使用他类药物.
- 倾向性得分匹配 (PSM) 在他类药物使用者和非使用者之间平衡的基线特征.
主要成果:
- 类固醇使用与20%降低痴呆风险 (aHR,0.80) 和43%降低全因死亡风险 (aHR,0.57) 相联系.
- 观察到一种剂量-反应关系,较高的他类cDDD与更大的痴呆症风险降低相关.
- 这项研究包括35426对匹配的对.
结论:
- 类固醇药物治疗与老年T2DM患者的痴呆风险和死亡率降低有关,这些患者有 delirium 的病史.
- 较高的他类药物剂量和强度似乎更有益.
- 需要进一步的随机对照试验来证实这些发现.
相关概念视频
Alzheimer's Disease: Treatment
744
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
744
Dementia
482
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
482
Drug Dosing: Geriatric Patients
206
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
206
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
1.3K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.3K
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism
178
Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
178
Pharmacodynamics in Geriatric Patients: Effects of Age
174
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
174

